Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study

被引：0
|
作者：
Pasquale Mone
Giuseppe Martinelli
Angela Lucariello
Anna Luisa Leo
Anna Marro
Stefano De Gennaro
Stefania Marzocco
Divina Moriello
Salvatore Frullone
Luigi Cobellis
Gaetano Santulli
机构：
[1] Albert Einstein College of Medicine,Department of Medicine, Division of Cardiology, Einstein Institute for Aging Research, Fleischer Institute for Diabetes Research (FIDAM), Einstein
[2] ASL Avellino, Mount Sinai Diabetes Research Center (ES
[3] University of Campania “Luigi Vanvitelli”,DRC)
[4] Parthenope University Naples,Department of Pharmacy
[5] University of Salerno,Department of Molecular Pharmacology, Institute for Neuroimmunology and Inflammation (INI)
[6] Albert Einstein College of Medicine,undefined
来源：
Cardiovascular Diabetology | / 22卷
关键词：
Aging; Biguanides; Cognitive dysfunction; Frailty; Hyperglycemia; Menopause; Metformin; Sex differences; Women’s health;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study
    Mone, Pasquale
    Martinelli, Giuseppe
    Lucariello, Angela
    Leo, Anna Luisa
    Marro, Anna
    De Gennaro, Stefano
    Marzocco, Stefania
    Moriello, Divina
    Frullone, Salvatore
    Cobellis, Luigi
    Santulli, Gaetano
    CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
  • [2] Gastrointestinal tolerability of extended-release metformin tablets compared to immediaterelease metformin tablets: results of a retrospective cohort study
    Blonde, L
    Dailey, GE
    Jabbour, SA
    Reasner, CA
    Mills, DJ
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (04) : 565 - 572
  • [3] Effect of Combining Extended-Release Carvedilol and Lisinopril in Hypertension: Results of the COSMOS Study
    Bakris, George L.
    Iyengar, Malini
    Lukas, Mary Ann
    Ordronneau, Paul
    Weber, Michael A.
    JOURNAL OF CLINICAL HYPERTENSION, 2010, 12 (09): : 678 - 686
  • [4] The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study
    Gao, H.
    Xiao, W.
    Wang, C.
    Zhang, J.
    Yang, Y.
    Yang, J.
    Yang, W.
    Hong, T.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2008, 62 (05) : 695 - 700
  • [5] Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
    Mone, Pasquale
    Lombardi, Angela
    Gambardella, Jessica
    Pansini, Antonella
    Macina, Gaetano
    Morgante, Maria
    Frullone, Salvatore
    Santulli, Gaetano
    DIABETES CARE, 2022, 45 (05) : 1247 - 1251
  • [6] Addition of once-daily extended-release metformin to sulfonylurea significantly improves glycemic control in patients with type 2 diabetes
    Schwartz, Sherwyn
    Berner, Bret
    Cramer, Marilou
    Chiang, Yu-Kun
    Lewin, Andrew
    DIABETES, 2006, 55 : A463 - A463
  • [7] Aerobic Gait Training in Older Adults With Mild Cognitive Impairment and Hypertension: Preliminary Results.
    Koblinsky, Noah
    DeCaria, Joseph
    Montero-Odasso, Manuel
    Petrella, Robert
    MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2012, 44 : 533 - 533
  • [8] Patient adherence to and tolerability of treatment with metformin extended-release formulation in patients with type 2 diabetes. GLUCOMP study
    Strojek, Krzysztof
    Kurzeja, Anna
    Gottwald-Hostalek, Ulrike
    CLINICAL DIABETOLOGY, 2016, 5 (01): : 15 - 21
  • [9] Improving Type 2 Diabetes Care with Extended-Release Metformin: Real-Life Insights from a Physician Educational Program
    Molteni, Laura
    Marelli, Giuseppe
    Castagna, Giona
    Brambilla, Luciano
    Acerbis, Maurizio
    Alberghina, Fabio
    Carpani, Antonio
    Chiavenna, Erika
    Ferlini, Maria Grazia
    Impellizzeri, Carmen
    Paredi, Roberto
    Rigamonti, Alberto
    Rivolta, Giuseppe
    Disoteo, Olga Eugenia
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2024, 24 (12) : 1422 - 1430
  • [10] Cost-effectiveness analysis of switching type-2 diabetes patients from immediate-release metformin (Glucophage®) to a new extended-release formulation of metformin (Glucophage®xr)
    Renaudin, C
    Roze, S
    Valentine, WJ
    Palmer, AJ
    VALUE IN HEALTH, 2004, 7 (06) : 739 - 739
12345